SonaCare Medical Primed for Success in the New Year after Strong Finish in 2015

Physicians across the United States are adopting Sonablate® as the preferred prostate tissue ablation device.

CHARLOTTE, N.C., January 5, 2016 -- SonaCare Medical, LLC, a pioneer in minimally invasive high intensity focused ultrasound (HIFU) technologies, and first to receive FDA regulatory authorization for the ablation of prostate tissue, reports impressive Q4 growth in 2015 since receiving a de novo grant from the Food and Drug Administration (FDA) to market and sell Sonablate® in the United States in October, 2015.

This grant created a new product class for urologic HIFU medical devices and paved the way for urologic HIFU ablation technologies to enter the U.S. market. Post grant, there have been 14 sales of Sonablate technology in the U.S. with eight systems installed to date, five of which have been used. Sonablate® already has been used to deliver 23 HIFU prostate tissue ablations in the U.S. post commercial launch, including whole gland ablations, hemi-ablations, and true focal ablations using MRI-US fused image guidance.  According to Paul LaPine, V.P. Sales, "The response from the urology community since we received our grant has been extremely favorable.  There is a large base of urologists in the U.S. experienced in the use of Sonablate due to their participation in our concierge medical program outside the U.S. and our clinical trials in the U.S.  This has provided us with a robust sales funnel of physicians who are eager to deliver this type of care in the geographic region where they practice.  In addition, academic departments have been waiting for a long time to be able to offer tissue sparing options to their patients and are looking to HIFU in general, and Sonablate specifically, to provide this ability."     

Sonablate regulatory authorization in the U.S. has had a positive effect across borders as well. Since the October grant, three new international distributors have been trained and three new countries have adopted Sonablate technology. Vice President of International Operations, Alex Gonzalez, comments, "The international response for the latest Sonablate technology post FDA clearance has been significant. Sonablate® HIFU technology has made its debut in five new countries since the start of 2015 and the substantial early demand in the U.S. is indicative of the great momentum that exists at a worldwide level." In addition to Sonablate prostate ablations performed on an ongoing and regular basis at sites in Germany, England, and Switzerland, SonaCare Medical technology also was used recently in Switzerland to deliver an open kidney ablation in a patient with a single kidney for whom tissue preservation was considered essential. 

"We are thrilled at the early response to our introduction of Sonablate in the U.S. and the continued interest overseas, and expect widespread worldwide dissemination of the technology over the course of 2016", states Mark Carol, SonaCare Medical CEO. "It is an exciting time in the field of whole gland and focal soft tissue ablation, and SonaCare is delighted to be at the forefront of applications of this capability in the prostate and the kidney."

Sonablate® is the first device to receive regulatory authorization from the FDA for the focused ultrasound ablation of prostate tissue. Since its introduction over 15 years ago, Sonablate®technology has been used around the world on nearly 15,000 patients in over 30 countries, including approximately 4,000 U.S. men who have had this procedure performed outside the U.S. 

About SonaCare Medical, LLC
SonaCare Medical is a world leader in minimally invasive focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing focused ultrasound related technologies that support precise and innovative procedures for the treatment of a range of medical conditions. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures medical devices, including the following: Sonablate®, which has 510(K) clearance in the U.S. under a De Novo regulatory classification; Sonablate® 500, which has CE Marking and has obtained regulatory authorization in more than 49 countries outside the U.S.; Sonatherm® laparoscopic HIFU surgical ablation system, which has 510(K) clearance in the U.S., has CE Marking and has obtained regulatory authorization in more than 30 countries outside the U.S.

For additional information, visit 

SonaCare Medical, LLC
Erica Griffith (704) 936-1834, This email address is being protected from spambots. You need JavaScript enabled to view it.

Forward Looking Statements. 
The Company's forward-looking statements are based on management's current expectations and assumptions regarding the Company's business and performance, the economy and other future conditions and forecasts of future events, circumstances and results. As with any projection or forecast, forward-looking statements are inherently susceptible to uncertainty and changes in circumstances. The Company's actual results may vary materially from those expressed or implied in its forward-looking statements. Any forward-looking statement made by the Company speaks only as of the date on which it is made. The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, subsequent events or other factors.


HIFU company

Latest News

17 May 2018

SonaCare Medical congratulates Naren Sanghvi on his receipt of The William and Francis Fry Honorary Fellowship for Contributions to Therapeutic Ultrasound

10 April 2018

Over 120 urologists gather at Imperial College London to learn new diagnostic techniques and minimally invasive focal approaches for treating prostate cancer.